Impact of a Telemonitoring Device on the Occurever at Home in Children at Risk of Chemotherapy-Induced Neutropenia
TELEDOM
1 other identifier
interventional
30
0 countries
N/A
Brief Summary
The goal of this clinical trial is to evaluate the feasibility of the study, measured by the acceptability rate of patients to be recruited in a study proposing temperature monitoring at home, by a remote monitoring device or by the visit of an IDE at home (in association with the usual educational sessions), to children at risk of febrile neutropenia, from families with psycho-social vulnerabilities. The main questions it aims to answer are:
- Will participants adhere to the telemonitoring system?
- Is the intervention feasible, in terms of the device's failure to record temperature data?
- Will parents behave appropriately when using the device?
- How satisfied will parents and caregivers be?
- What will be the physical tolerance of the device?
- On an exploratory basis, will the remote monitoring system be effective for months? Researchers will compare :
- patients using the telemonitoring device for continuous temperature monitoring at home, in combination with education sessions on temperature monitoring and the device
- with patient with temperature monitoring at home by a nurse, 2 times a day, in combination with education sessions on temperature monitoring (without the telemonitoring device at home)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started May 2026
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 18, 2024
CompletedFirst Posted
Study publicly available on registry
November 20, 2024
CompletedStudy Start
First participant enrolled
May 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 4, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 4, 2028
January 20, 2026
January 1, 2026
2 years
November 18, 2024
January 16, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
study acceptability rate
number of patients included/number of eligible patients offered the study.
24 months
Study Arms (2)
remote temperature monitoring device
EXPERIMENTALhome temperature monitoring by a nurse
ACTIVE COMPARATORInterventions
* Home temperature monitoring by a nyrse, twice a day, * In association with education sessions on temperature monitoring.
* Use of the Tucky® remote monitoring device for continuous temperature monitoring at home, * In combination with education sessions on temperature monitoring and the device.
Eligibility Criteria
You may qualify if:
- patient
- Aged 0 to 17 inclusive
- Followed in the Pediatric Onco-Hematology Department
- Primo-diagnosed with solid or hematological cancer (incident case)
- Having received a first cycle of chemotherapy
- Whose family has psycho-social vulnerabilities assessed by the Froger et al. tool, indicating a need for an IDE to support the family in monitoring the patient.
You may not qualify if:
- Patient:
- with a dermatosis contraindicating the use of the device
- Refusing to participate in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 18, 2024
First Posted
November 20, 2024
Study Start
May 1, 2026
Primary Completion (Estimated)
May 4, 2028
Study Completion (Estimated)
May 4, 2028
Last Updated
January 20, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share